Needham & Company
View Older Stories
-
Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...)
-
Seattle Genetics (SGEN) PT Raised to $188 at Needham & Company on Drug Platform Expansion
-
Seattle Genetics (SGEN) PT Raised to $188 at Needham & Company
-
Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference
-
Seattle Genetics (SGEN) PT Raised to $135 at Needham & Company, Following Approval of Bladder Cancer Drug
-
Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
-
Seattle Genetics (SGEN) PT Raised to $121 at Needham & Company
-
Pre-Open 10/21: (MDR) (OPK) (FSCT) Higher (KMT) (IPHS) (BA) Lower (more...)
-
Seattle Genetics (SGEN) Reports Strong Data at ESMO
-
Seattle Genetics (SGEN) PT Raised to $81 at Needham & Company
-
Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
-
Needham & Company Reiterates Buy Rating and $72 PT on Seattle Genetics (SGEN) Following Discontinuation of Vadastuximab Development; 'Buy on Weakness Ahead of ESCHELON-1'
-
Needham & Company Tells Seattle Genetics (SGEN) Investors Not to Overreact About Vadastuximab Clinical Hold
-
Streetinsider.com's Hot Lunchtime Reads 8/1: (AXTA) (SCTY) (XON) (SGEN)
-
Seattle Genetics (SGEN): Adcetris Could Become a Blockbuster - Needham
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Seattle Genetics (SGEN) Delivers at ASH - Needham & Company
-
Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
-
Seattle Genetics Announces Exercise of Over-Allotment Option
-
Seattle Genetics (SGEN) Prices 11.7M Common Stock Offering at $41/Share
-
Seattle Genetics Announces Pricing of Public Offering of Common Stock
-
Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval
-
Needham & Company Maintians Bullish Stance on Seattle Genetic (SGEN) Amid AETHERA Data
-
Notable Analyst Rating Changes 05/06: (VLO) (BBG) (SCHW) Upgraded; (TGT) (DCT) (FN) Downgraded
-
Pre-Open Stock Movers 2/12: (OC) (CSTE) (TRIP) Higher; (VTUS) (RLOC) (PRGN) Lower (more...)
-
Needham & Company Upgrades Seattle Genetics (SGEN) to Buy; Could Be Next Large Cap Drug Co.
-
StreetInsider.com Notable Analyst Rating Changes 02/13: (GRPN) (NNA) (UTIW) Upgraded; (FOSL) (SGEN) (SAPE) Downgraded
-
Needham & Company Downgrades Seattle Genetics (SGEN) to Hold
-
Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
-
Notable 52-Week Highs and Lows of the Day 06/08: (SGEN) (NEON) (DG) High; (ANR) (ACI) (AUO) Low
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Impressive First Full Quarter of Adcetris Sales
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2012 Preview
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Adcetris Data in Combination with AVD Supportive of Potential Role in Front Line Therapy
-
Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
-
Needham & Company Assumes Coverage on Seattle Genetics (SGEN) at Buy; 3Q11 Review and ASH Meeting Preview
-
Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics; As the School Year Begins, So Does Commercial Life for SGEN
-
Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS
-
Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); ASCO Meeting Highlights Include Durable Responses Induced By B. Vedotin
-
Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising PT
-
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Trials/Other Pipeline Data Set the 2011 Mission
-
Seattle Genetics (SGEN) To Offer Common Shares
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2011 May Be a Transformational Year
-
Needham & Company reiterates a 'Buy' on Seattle Genetics (SGEN); B is for BLA, and Ved is for Very Exemplary Data - Pivotal Trial Results
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN)
-
Needham & Company Lifts Target On Seattle Genetics (SGEN) Following Positive Data